Evaluating efficacy of a novel dentifrice in reducing probing depths in Stage I and II periodontitis maintenance patients: A randomized, double‐blind, positive controlled clinical trial

Background Compliance to periodontal maintenance therapy (PMT) is essential for long‐term periodontal health. Between PMT visits, patients must maintain good oral hygiene. A dentifrice with demonstrable clinical benefits for use between PMT visits would be highly desirable. The aim of this clinical...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of periodontology (1970) Ročník 92; číslo 9; s. 1286 - 1294
Hlavní autoři: Kaur, Maninder, Geurs, Nicolaas C., Cobb, Charles M., Otomo‐Corgel, Joan, Takesh, Thair, Lee, June H., Lam, Tracie M., Lin, Kairong, Nguyen, Audrey, Nguyen, Brian L., Wilder‐Smith, Petra
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.09.2021
Témata:
anti‐inflammatory agents
Dental Plaque Index
Dentifrices - therapeutic use
Double-Blind Method
Gingivitis
Humans
oral hygiene
periodontitis
Periodontitis - drug therapy
Periodontitis - prevention & control
plaque control
Tin Fluorides
toothbrushing
toothbrushing
oral hygiene
anti-inflammatory agents
plaque control
periodontitis
ISSN:0022-3492, 1943-3670, 1943-3670
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background Compliance to periodontal maintenance therapy (PMT) is essential for long‐term periodontal health. Between PMT visits, patients must maintain good oral hygiene. A dentifrice with demonstrable clinical benefits for use between PMT visits would be highly desirable. The aim of this clinical study was to investigate the effect of a novel dental gel on probing depths (PD) and inflammation when used as a home care dentifrice in Stage I and II periodontitis patients. Methods This double‐blind clinical study randomized 65 subjects with Stage I and II periodontitis to the novel dental gel containing 2.6% EDTA, and a commercially available anti‐gingivitis dentifrice with 0.454% stannous fluoride. Primary endpoint was PD at 6 months for those sites with baseline PD ≥ 4 mm and secondary endpoints included whole mouth mean scores of modified gingival index (MGI), modified sulcus bleeding index (mSBI) and plaque index (PI). No SRP was performed at baseline. Results Subjects using the novel dentifrice showed significant PD reductions of 1.18 mm (from 4.27 mm at baseline to 3.09 mm at 6 months) compared to 0.93 mm (from 4.23 mm at baseline to 3.30 mm at 6 months) shown for those using the positive control dentifrice. Difference between treatments at 6 months was 0.21 mm with P‐value = 0.0126. Significant improvements in MGI (P = 0.0000), mSBI (P = 0.0000), and PI (P = 0.0102) were also observed in 6 months. Conclusion The novel dentifrice showed significant reductions in PD and gingival inflammation over 6 months solely as a home care dentifrice without baseline SRP in Stage I and II periodontitis maintenance patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0022-3492
1943-3670
1943-3670
DOI:10.1002/JPER.20-0721